ScholarWorks@Gachon: Park, Jinny

Detailed Information

Park, Jinny (박진희)

College of Medicine (Department of Medicine)

Research Area

Tel 032-460-2629
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Prognosis:9||Chemotherapy:7||Rituximab:6||prognosis:5||Lymphoma:5||Acute myeloid leukemia:5||Diffuse large Bcell lymphoma:5||Chronic myeloid leukemia:3||Gastric cancer:3||Oxaliplatin:3||diffuse large Bcell lymphoma:3||Bone marrow:3||Hematopoietic stem cell transplantation:3||Hematological malignancy:2||Primary myelofibrosis:2||Autologous transplantation:2||Pyrosequencing:2||MDS:2||NonHodgkin lymphoma:2||Nonsmall cell lung carcinoma:2||advance directive:2||Hypomethylating agent:2||protein kinase C:2||Secondline:2||Elderly:2||itraconazole:2||Polycythemia vera:2||lenalidomide:2||Korea:2||malignancy:2||Cisplatin:2||chronic myeloid leukemia:2||Practice guideline:2||Cytogenetics:1||Cytotoxicity:1||Dapsone therapy:1||Decitabine:1||Diffuse large B cell lymphoma:1||Diffuse large bcell lymphoma:1||Diffuse large cell lymphoma:1||Direct sequencing:1||Docetaxel:1||Drug Resistance:1||Drug therapy:1||EGFR:1||EGFR TKI:1||Elderly AML:1||Empirical Antifungal Therapy:1||Empirical antifungal therapy:1||Epidermal growth factor receptor:1||Epirubicin:1||Exon 20:1||Extranodal NK/Tcell lymphoma:1||FDGPET/CT:1||Ferritin:1||Firstline:1||Fragment analysis:1||Galactomannan Test:1||Gefitinib:1||Gemcitabine:1||Genetics:1||Glucocorticoids:1||Gold Nanoparticles:1||HER2:1||Hematological Malignancy:1||Hepatitis B:1||Hepatitis B Core Antigen:1||Hydroxy itraconazole:1||Hydroxyurea:1||IPSS:1||Immune thrombocytopenia:1||Immunochemotherapy:1||Immunohistochemistry:1||Immunostaining:1||Induction:1||Induction chemotherapy:1||Infection:1||Infusionrelated reaction:1||Intolerance:1||Irinotecan:1||Itraconazole:1||KIT:1||KRAS mutation:1||Ki67:1||Korean:1||LRPSS:1||Lactate dehydrogenase:1||LowerRisk Prognostic Scoring System:1||MCF7 cells:1||MMP9:1||MTT and TUNEL Assay:1||Marginal zone:1||Marginal zone lymphoma:1||Mature Tcell neoplasm:1||Metabolic tumor volume:1||Molecular response:1||Monomorphic epitheliotropic intestinal Tcell lymphoma:1||Mutation:1||Mutations:1||Myelodysplastic syndrome:1||Nras:1||NKcell activity:1||Neural Progenitor Cell:1||Neutropenia:1||Nilotinib:1||Nonsmall cell lung cancer:1||Pancreatic neoplasms:1||Pemetrexed:1||Philadelphia chromosome positive:1||Plasma exchange:1||Polycythemia Vera:1||Population study:1||Positronemission tomography:1||Postmarketing surveillance:1||Predictive factor:1||Prognostic groups:1||Pseudolymphoma:1||Purpura:1||Receptor, epidermal growth factor:1||Renal insufficiency:1||Resection:1||Response:1||S1:1||Sanger sequencing:1||Sarcopenia:1||Screening:1||Screening PCR:1||Small cell lung carcinoma:1||Splenectomy:1||Stem cell transplantation:1||Stomach cancer:1||Survival:1||Survival analysis:1||Therapeutic drug monitoring:1||Thrombocythemia:1||Thrombocythemia, essential:1||Thrombomodulin:1||Thrombotic microangiopathies:1||Thrombotic thrombocytopenic:1||Trastuzumab:1||Tumor burden:1||Tyrosine kinase inhibitor:1||Ultradeep sequencing:1||Waldeyer&apos:1||acute myeloid leukaemia:1||acute myeloid leukemia:1||antiinflammatory:1||antioxidant:1||apos:1||attitudes:1||autologous stem cell transplantation:1||azacitidine:1||biomarkers:1||bone marrow involvement:1||breast cancer:1||caregivers:1||chemotherapy:1||chronic myeloid leukaemia:1||clinical response:1||clonality:1||comparison:1||copanlisib:1||decitabine:1||droplet digital polymerase chain reaction:1||dyad:1||empirical antifungal therapy:1||epsteinbarr virus:1||essential:1||essential thrombocythemia:1||gemcitabine:1||genome wide single nucleotide polymorphism array:1||hematologic stem cell transplant:1||hematology:1||high risk:1||hyaluronic acid:1||hyaluronic acid synthase:1||imatinib:1||imatinib cessation:1||imatinib trough concentration:1||invasion:1||knowledge:1||longterm data:1||lung cancer:1||marginal zone lymphoma:1||matriptase:1||matrix metalloproteinase9:1||medical imaging:1||molecular response:1||myelodysplastic syndromes:1||myeloproliferative neoplasms:1||nasal type:1||neoplasm invasiveness:1||newly diagnosed:1||nilotinib:1||nonHodgkin&apos:1||nonsmall cell lung cancer:1||normal karyotype:1||nuclear diameter:1||p53:1||peripheral Tcell lymphoma:1||phase I/II trial:1||phase IV clinical trial:1||plantderived unsaturated fatty acid:1||prednisone:1||proteaseactivated receptor2:1||qualityoflife:1||radotinib:1||refractory:1||relapse:1||relapsed or refractory:1||s agammaglobulinemia tyrosine kinase:1||s lymphoma:1||s ring:1||smoking:1||surveillance:1||transcript type:1||treatmentfree remission:1||tyrosine kinase inhibitor:1||글루코코르티코이드:1||급성 골수성 백혈병:1||리툭시맙:1||림프종:1||무형성빈혈:1||조혈모세포이식:1||항암제:1||항암화학요법:1||핵심항원:1||혈장교환술:1||혈전성혈소판감소자반증:1||혈전혈관병증:1||18 FFDG PET/CT:1||호중구 감소증:1||ABCG:1||AML:1||Adult:1||Anagrelide:1||Anemia:1||Antibiotic prophylaxis:1||Aplastic anemia:1||Atypical hemolytic uremic syndrome:1||Autologous peripheral blood stem cell transplant:1||BCRABL1 tyrosine kinase:1||BIOMED2:1||Bacterial infection:1||Belotecan:1||Bloodstream infection:1||Bone marrow involvement:1||Bortezomib:1||Brain metastases:1||Bruton&:1||B형 간염:1||Creactive protein:1||CALR:1||CD30:1||CD99:1||CML:1||CVP:1||Capecitabine:1||Carcinoma, nonsmallcell lung:1||Chop14:1||Chromosomal abnormalities:1||Consolidation:1||Core binding factorpositive acute myeloid leukemia:1||CrELfree paclitaxel:1||

STATISTICS: Total View :4,136,558; Today View :4,237

RSS_1.0 RSS_2.0 ATOM_1.0

1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE